Remove Immunization Remove Labelling Remove Presentation
article thumbnail

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Pharmacy Times

These conclusions were presented as part of an abstract from the open-label, phase 3 CheckMate 816 trial (NCT02998528) at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, and subsequently published in the Journal of Clinical Oncology. J Clin Oncol. 2025;43(17). doi:10.1200/JCO.2025.43.17_suppl.LBA800.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Patients often present with peripheral blood, bone marrow, and splenic involvement. 5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. There is currently no universal standard of care for MCL.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Pharmacy Times

1 The findings were presented at the Revolutionizing Atopic Dermatitis (RAD) 2025 conference held in Nashville, Tennessee. The results confirm nemolizumab’s use in increasing improvements in symptoms, such as itch and skin lesions, with prolonged treatment up to 2 years.

article thumbnail

Once-Daily Alixorexton Improves Wakefulness at All Doses in Patients With Narcolepsy Type 1

Pharmacy Times

Alixorexton presents as a hopeful, potentially paradigm-shifting treatment for this population. In a sign of alixorexton’s tolerability, over 95% of patients who participated in this portion of the trial elected to join the ongoing 7-week, open-label extension.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. Presented at: Hematology/Oncology Pharmacy Association 2025 Annual Conference; April 9-12, 2025; Portland, OR. REFERENCE Soefje SA.

FDA
article thumbnail

Results Find SGLT2 Inhibitors Associated With Erythrocytosis

Drug Topics

The Opportunities, Gaps in Diabetes Care Making Pharmacists Stand Out | ADA 2025 Brian Nowosielski ; Jon Easter, RPh July 4th 2025 Podcast Following his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter caught up with Drug Topics to discuss the pharmacists’ role in diabetes management.

article thumbnail

How AI Brings Pharmacogenetics to the Frontline of Precision Medicine

Pharmacy Times

This change mirrored a January 2025 FDA safety alert and label update that urged providers to consider genetic testing, inform patients of the risks, and discuss available options. Demonstrating improved outcomes and cost-effectiveness helps ensure payer support and broadens access to precision therapies.